Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Missouri-Columbia
There are currently two different genetic tests that have been developed for this purpose. They both look at specific DNA components to determine the risk. Participants in the study will be over the age of 60 years and caucasian as this is the population of people in which these tests have been validated. Each participant will have the study explained to them and then will be asked to sign the informed consent document if they agree to participate. They will have a dilated exam of their eyes along with photographs taken of the retina. If their doctor sees that it is necessary they will also have a special scan or a special angiogram of their eyes to look at their retina in more detail. For the genetic testing a member of the research team will use two swabs from each of the genetic companies to gently scrap some cells from the inside of the cheek. These cells will be sent to each respective lab for analysis.
Age
60–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Caucasian race
Age \>/= 60 years
Patient's written informed consent
Ability to comply with the protocol procedures
You may not be if
Race other than Caucasian
Age \< 60 years
Macular or retinal pathology other than ARMD
Known hypersensitivity to any drug included in the treatment protocol
Any other severe clinical condition that in the judgment of the local investigator would place the patient at undue risk or interfere with the study completion
Prisoners
Clareo Health | PIIR Study: Comparison of Genetic Tests for Age-Related Macular Degeneration
